Ruti Aga Banned for Six Years: Forged Medical Prescription Ends Marathon Runner's Career

The Athletics Integrity Unit (AIU) has imposed a six-year ban on Ethiopian marathon runner Ruti Aga. This case goes far beyond an ordinary doping violation. After winning a half marathon in China last March, Aga's sample tested positive for methylprednisolone. The route she chose to defend herself cost her almost the entirety of her sporting career—a forged medical prescription. The official AIU statement confirms that the sanction is built from two separate charges, and their arithmetic is the real story of this case. According to the AIU, Aga received a two-year sanction for a presence violation and a four-year sanction for tampering. The total six-year ban is effective from 10 September, the date her provisional suspension began. Procedurally, backdating is no relief, since time served under provisional suspension is credited to the ban anyway. It also signals that the panel rejected any no-significant-fault mitigation that could have reduced the presence charge. Now the technical detail that early reports got wrong. Methylprednisolone was described as a 'prohibited steroid,' whereas it is in fact a glucocorticoid, listed under class S9 of the WADA Prohibited List—not S1, the anabolic steroid class. The difference is not merely semantic. S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. The direct implication is that an injection administered out-of-competition for a knee injury is entirely lawful. A violation arises only if residues are present in an in-competition sample. In road running this timing window is decisive. A road race's testing window opens at 23:59 on the day before the race. So if a runner receives an injection days before the race and residue remains, she will be caught. That is exactly what happened in Aga's case. The irony is that she did have a legitimate defence available—proving the injury, the route and the timing. AIU's investigation found that Aga cited a methylprednisolone injection to treat a knee injury and submitted a prescription in support. The investigation established that the prescription had been issued by a family member who was not a registered physician. That person claimed to have used an 'old prescription pad from a former workplace.' The clinic named on the prescription did not actually exist, and the clinic's management explicitly disowned any connection to the document. These are three separate verification failures: a clinic that does not exist, a person with no medical registration, and a document its purported issuer rejects. Beyond that, misleading information was given in investigative interviews, which led to the separate tampering charge. That charge was not confined to the document—it was also tied to statements made during questioning. This is a self-inflicted, career-terminal case. Had only the presence violation stood, the ban would have been two years, potentially reducible given the injury context. But the four years for tampering turned it into six. The real damage is that the forgery destroyed the one legitimate defence that might have worked. The injury and its treatment were real—such injections for knee synovitis are standard sports-medicine practice in distance runners—but the documents were fake. On Aga's sporting record, she won the 2026 Tokyo Marathon, one of the most prestigious races of that era. She also finished second three times at World Marathon Majors. Her personal best is understood to be around 2:18:34, set at the 2026 Berlin Marathon. That mark placed her among the elite marathoners of her generation, although she never won a global championship medal. For the 32-year-old Aga, a six-year ban is effectively the end of her career. By the time the ban, effective from 10 September, expires, she will be around 38. The depth of Ethiopian women's marathoning is such that even a 2:18 performer cannot be certain of national team selection—and for a 38-year-old with a doping record, that route is considered all but closed. She is entirely outside the 2028 Olympic cycle. The result and prize money from the Chinese half marathon in March where her sample was collected will almost certainly be forfeited, though reports have not stated the disqualification scope explicitly. Under standard AIU practice, the competition at which the sample was taken is automatically disqualified, and ranking points accrued after that date are voided. The 2026 Tokyo title and earlier results generally stand, since the violation is anchored to a later date. Aga's case is a warning in itself. A substance with no proven endurance benefit became the basis for a six-year ban—but the substance was not the real cause. The real cause was that a knee injury was treated within a system that was medically void and formally void. Aga had no qualified team physician, no therapeutic use exemption (TUE), and no formal medical records. When no legitimate route to help appeared, a forged prescription was manufactured. This is a recurring pattern in East African road-running entourages. Injured marathoners face pressure to demonstrate form, because appearance fees are a large share of their income. That makes glucocorticoids the cheapest and most accessible means of masking pain. When medical support is informal, documents become informal too—and that is where forgery begins. The case is seen as part of a broader cluster of AIU cases against East African road runners, in which an initial violation frequently escalates into the more serious charge of tampering. The implication is that the enforcement frontier is shifting from sample testing toward document verification. Competitively, this ban will have no measurable effect on Ethiopia or the global women's marathon landscape. Aga held no global championship medals, so her removal does not alter Ethiopia's medal capacity. The impact is instead administrative and commercial: a runner who won a Major and finished second three times will now be regarded as commercially radioactive, in a sport where distance-running sponsorship is already thin. China's label-race circuit has also been drawn into the discussion. Large appearance-fee budgets, deep East African elite fields and expanding AIU testing combine to make this tier of racing a high-integrity-risk zone. It is also worth noting that Aga's post-2026 racing pattern consisted of selective Major appearances and Asian label races—few starts, higher appearance fees. That model is normal for a 2:18–2:20 marathoner, and it is now becoming the AIU's highest-yield testing ground. Legal options are not yet closed. An appeal to the Court of Arbitration for Sport (CAS) is typically available for around 21 days from the reasoned decision. But the finding here rests on document forgery and is extremely hard to overturn. There is a further dimension outside AIU's jurisdiction—criminal exposure for document forgery. That falls within national law enforcement's remit, and action in that direction remains possible. Finally, there is a lesson here for sports journalism as well. Lumping glucocorticoids and anabolic steroids into a single category is not merely technically wrong; it frames the severity of such cases in the wrong context. Aga's error was not legitimate medicine—that was legitimate—but a failure of healthcare accountability, followed by a failure of internal integrity. At 32, a six-year ban is a technical penalty, but its effect is indistinguishable from the end of a career. The Tokyo title will always remain in her record, but every line after it will be tied to a forged prescription.